Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy - Neovascular (exudative) maculopathy - Choroidal neovascularization (CNV), polypoidal choroidal vasculopathy (PCV), reticular pseudodrusen, or retinal angiomatous proliferation
Decreased central vision and distortion of seeing straight lines are the most common symptoms.
New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Dietary nitrate intake contributes to a lower risk of age-related macular disease, although this association seems to disappear when Mediterranean dietary patterns are taken into account, according to a study.
Patients with early age-related macular degeneration (eAMD) appear to have increased serum cholesterol efflux capacity, according to a recent Singapore study. The same is true for polypoidal choroidal vasculopathy (PCV), but not for typical neovascular AMD (tAMD).
In neovascular age-related macular degeneration (nAMD), the absence of exudative recurrence after three loading doses of antivascular endothelial growth factor (VEGF) is associated with younger age, smaller lesion size, and having no fibrovascular pigment epithelial detachment (PED), a recent study has found.
The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
New drug applications approved by US FDA as of 01 - 15 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.